Roivant Sciences is a biopharmaceutical company that builds and incubates focused drug-development subsidiaries often called “Vants.” Each unit typically concentrates on a specific therapeutic program or technology, with Roivant providing capital, operational support and portfolio oversight. The model aims to advance late-stage or deprioritized assets more efficiently than a single large pipeline under one roof.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 2.2 | — | -223.3 | — |
| Q3 2025 | 1.6 | — | -113.5 | — |
| Q4 2025 | 2 | — | -265.9 | — |
| Q1 2026 | 2.5 | — | 303 | — |
| Q2 2026 | 1.4 | -33.5% | -189.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Fox Corporation (FOX), First Citizens BancShares, Inc. (FCNCA), Symbotic Inc. (SYM), Arxis, Inc. (ARXS), Dollar Tree, Inc. (DLTR), Principal Financial Group, Inc. (PFG)